Wasatch Advisors LP Sells 20,327 Shares of AtriCure, Inc. $ATRC

Wasatch Advisors LP lowered its position in shares of AtriCure, Inc. (NASDAQ:ATRC) by 8.0% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 233,604 shares of the medical device company’s stock after selling 20,327 shares during the period. Wasatch Advisors LP’s holdings in AtriCure were worth $6,536,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ATRC. Vanguard Group Inc. increased its stake in shares of AtriCure by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock worth $193,993,000 after acquiring an additional 62,861 shares in the last quarter. Wellington Management Group LLP boosted its stake in AtriCure by 8.1% during the third quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company’s stock worth $151,296,000 after acquiring an additional 322,818 shares in the last quarter. First Light Asset Management LLC boosted its stake in AtriCure by 32.0% during the fourth quarter. First Light Asset Management LLC now owns 1,175,445 shares of the medical device company’s stock worth $46,501,000 after acquiring an additional 285,083 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in AtriCure by 8.2% in the first quarter. Dimensional Fund Advisors LP now owns 997,759 shares of the medical device company’s stock worth $28,466,000 after purchasing an additional 75,862 shares during the period. Finally, GW&K Investment Management LLC grew its holdings in AtriCure by 10.6% in the fourth quarter. GW&K Investment Management LLC now owns 952,089 shares of the medical device company’s stock worth $37,665,000 after purchasing an additional 91,054 shares during the period. 99.11% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Sven Wehrwein sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $37.84, for a total value of $946,000.00. Following the transaction, the director directly owned 40,518 shares of the company’s stock, valued at approximately $1,533,201.12. This represents a 38.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Maggie Yuen sold 3,500 shares of the stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $38.42, for a total value of $134,470.00. Following the sale, the director owned 14,015 shares in the company, valued at approximately $538,456.30. This represents a 19.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 47,246 shares of company stock worth $1,777,845 over the last 90 days. 4.00% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. UBS Group lowered their target price on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, July 28th. Zacks Research upgraded AtriCure from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 24th. Canaccord Genuity Group raised their price objective on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Raymond James Financial set a $52.00 price objective on AtriCure in a research note on Tuesday, July 21st. Finally, Wall Street Zen downgraded AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, AtriCure presently has an average rating of “Moderate Buy” and an average target price of $48.50.

AtriCure Stock Up 1.4%

NASDAQ:ATRC opened at $43.56 on Thursday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The firm has a market cap of $2.22 billion, a P/E ratio of 207.44 and a beta of 1.20. AtriCure, Inc. has a fifty-two week low of $25.36 and a fifty-two week high of $43.84. The firm has a 50-day simple moving average of $33.24 and a two-hundred day simple moving average of $31.40.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The firm had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. During the same quarter in the prior year, the firm posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Analysts predict that AtriCure, Inc. will post 0.2 earnings per share for the current fiscal year.

AtriCure Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.